Mergers & Acquisitions ·
Crinetics Pharmaceuticals shareholders approved the proposed merger with Vertex Pharmaceuticals at a special meeting…
CRNXCrinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals shareholders approved the proposed merger with Vertex Pharmaceuticals at a special meeting on August 28, 2026. The Merger Proposal received 79,240,098 votes in favor against 13,618 opposed, satisfying the final outstanding condition for closing. A separate advisory vote regarding executive compensation related to the transaction failed, receiving only 33,854,149 votes for against 44,803,403 against; however, this result is non-binding and does not impede the merger. Crinetics anticipates the closing will occur on or about September 1, 2026. The company operates in the biotechnology industry, developing therapies for rare diseases.